BR0311177A - (imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmda - Google Patents
(imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmdaInfo
- Publication number
- BR0311177A BR0311177A BR0311177-6A BR0311177A BR0311177A BR 0311177 A BR0311177 A BR 0311177A BR 0311177 A BR0311177 A BR 0311177A BR 0311177 A BR0311177 A BR 0311177A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- neurodegeneration
- pyridazine
- imidazol
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"(IMIDAZOL-1-IL-METIL)-PIRIDAZINA COMO BLOQUEADOR DE RECEPTORES DE NMDA". A presente invenção refere-se a compostos da fórmula I onde A é um grupo cíclico não-substituído ou substituído; e R hidrogênio ou alquila inferior; e seus sais de adição de ácido farmaceuticamente aceitáveis. Demonstrou-se que os compostos das fórmulas IA e IB são bons bloqueadores específicos de subtipo de receptor NR-2B de NMDA. As indicações terapêuticas possíveis para estes compostos incluem formas agudas de neurodegeneração, causadas, por exemplo, por acidente vascular cerebral e traumatismo cerebral, e formas crónicas de neurodegeneração, tais como doença de Alzheimer, doença de Parkinson, doença de Huntington, ALS (esclerose amiotrófica lateral) e neurodegeneração associada a infecções bacterianas ou virais, e, além disso, depressão e dor crónica e aguda.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02010217 | 2002-05-16 | ||
PCT/EP2003/005151 WO2003097637A1 (en) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0311177A true BR0311177A (pt) | 2005-03-15 |
Family
ID=29433072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0311177-6A BR0311177A (pt) | 2002-05-16 | 2003-05-16 | (imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmda |
Country Status (31)
Country | Link |
---|---|
US (1) | US7005432B2 (pt) |
EP (1) | EP1506190B1 (pt) |
JP (1) | JP4267569B2 (pt) |
KR (1) | KR100632868B1 (pt) |
CN (1) | CN1312151C (pt) |
AR (1) | AR040010A1 (pt) |
AT (1) | ATE329912T1 (pt) |
AU (1) | AU2003242542B2 (pt) |
BR (1) | BR0311177A (pt) |
CA (1) | CA2485926C (pt) |
CL (1) | CL2004001251A1 (pt) |
CY (1) | CY1105159T1 (pt) |
DE (1) | DE60306152T2 (pt) |
DK (1) | DK1506190T3 (pt) |
ES (1) | ES2265581T3 (pt) |
HK (1) | HK1080845A1 (pt) |
HR (1) | HRP20041060B1 (pt) |
IL (1) | IL164922A (pt) |
MA (1) | MA27117A1 (pt) |
ME (1) | MEP76708A (pt) |
MX (1) | MXPA04011253A (pt) |
NO (1) | NO329605B1 (pt) |
NZ (1) | NZ536310A (pt) |
PL (1) | PL211340B1 (pt) |
PT (1) | PT1506190E (pt) |
RS (1) | RS51200B (pt) |
RU (1) | RU2317294C2 (pt) |
SI (1) | SI1506190T1 (pt) |
TN (1) | TNSN04224A1 (pt) |
WO (1) | WO2003097637A1 (pt) |
ZA (1) | ZA200408789B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
CN101171320B (zh) | 2005-05-03 | 2013-04-10 | 默克专利有限公司 | 有机电致发光器件 |
US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法 |
DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
CA2719749A1 (en) * | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
UY32417A (es) | 2009-02-05 | 2010-08-31 | Takeda Pharmaceutical | Compuestos de piridazinona |
WO2012018058A1 (ja) * | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2012019106A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
HUE049277T2 (hu) * | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Triazolok mint NR2B receptor inhibitorok |
CN109071488B (zh) | 2016-02-10 | 2021-08-13 | 詹森药业有限公司 | 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂 |
WO2017140771A1 (en) | 2016-02-18 | 2017-08-24 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
CR20210125A (es) | 2018-08-03 | 2021-06-30 | Cadent Therapeutics Inc | Moduladores del receptor nmda heteroaromático y usos de los mismos |
BR112021023562A2 (pt) | 2019-06-14 | 2022-01-04 | Janssen Pharmaceutica Nv | Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b |
JOP20210328A1 (ar) | 2019-06-14 | 2023-01-30 | Janssen Pharmaceutica Nv | مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b" |
WO2020249802A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
EP3983073A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1131031C (zh) | 1996-03-08 | 2003-12-17 | 弗·哈夫曼-拉罗切有限公司 | 作为nmda受体亚型阻断剂的4-苯基3,6-二氢-2h-吡啶基衍生物的应用 |
CA2220649C (en) | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | 4-hydroxy-piperidine derivatives |
US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
DE60105144T2 (de) | 2000-04-20 | 2005-09-08 | F. Hoffmann-La Roche Ag | Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen |
US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
US7022882B2 (en) | 2000-10-06 | 2006-04-04 | The Regents Of The University Of California | NMDA receptor channel blocker with neuroprotective activity |
CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active IP Right Cessation
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 EP EP03752750A patent/EP1506190B1/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 CA CA002485926A patent/CA2485926C/en not_active Expired - Fee Related
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/en active IP Right Grant
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
- 2004-11-12 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
-
2006
- 2006-01-18 HK HK06100801A patent/HK1080845A1/xx not_active IP Right Cessation
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0311177A (pt) | (imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmda | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
NO20062139L (no) | Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister | |
TN2009000199A1 (en) | Heteromonocyclic compound and use thereof | |
BR112014001642A2 (pt) | fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas e uso das mesmas como medicamento | |
BRPI0519287A2 (pt) | derivados de amida | |
BR112015012425A2 (pt) | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto | |
NZ705710A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
AR081154A1 (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y metodos de uso | |
BR112013025128A2 (pt) | derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson | |
BR0110233A (pt) | 4-benzil-1-[2-(4-hidróxi-fenóxi)-etil]-piperidina-3,4-diol | |
AR037249A1 (es) | Compuestos derivados de piridina, un procedimiento para prepararlos y medicamentos que los contienen | |
BR0211265A (pt) | Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor | |
NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
BR0214937A (pt) | Processo de preparação de derivados de equinocandina | |
IE912602A1 (en) | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | |
BR0011419A (pt) | Derivados de etanossulfonil-piperidina | |
WO2009148291A3 (en) | 3- or 4-substituted piperidine compounds | |
BR112023025396A2 (pt) | Compostos de 3-pirrolilsulfonamida como antagonistas de gpr17 | |
UA102087C2 (en) | 3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof | |
ECSP045426A (es) | (imidazol-1-il-metil)-piridazina como bloqueador del receptor nmda | |
BRPI0410613A (pt) | preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano | |
BR112021024398A2 (pt) | Processo alternativo para a preparação de ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-di-hidropirimidin-6-il]metil]-3-oxo-5,6,8,8a-tetra-hidro-1h-imidazo[1,5-a]pirazin-2-il]-carboxílico | |
BR0309025A (pt) | Agentes antidiabéticos | |
EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 403/06, C07D 409/14, A61K 31/505, A61P 25/00 Ipc: C07D 403/06 (2011.01), C07D 409/14 (2011.01), A61K |
|
B25A | Requested transfer of rights approved |
Owner name: EVOTEC INTERNATIONAL GMBH (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |